Atlas FDA

ORAQUICK HCV RAPID ANTIBODY TEST

FDA premarket approval P080027 · decided 2010-06-25

Approval details

PMA number
P080027
Trade name
ORAQUICK HCV RAPID ANTIBODY TEST
Generic name
Assay, enzyme linked immunosorbent, hepatitis c virus
Applicant
OraSure Technologies, Inc.
Date received
2008-10-24
Decision date
2010-06-25
Days to decision
609 days
Decision code
APRL
Product code
MZO
Advisory committee
Microbiology
Expedited review
No
Location
Bethlehem, PA
Statement
APPROVAL FOR THE ORAQUICK RAPID HCV ANTIBODY TEST. THE DEVICE IS INDICATED FOR THE QUALITATIVE DETECTION OF ANTIBODIES TO HEPATITIS C VIRUS (ANTI-HCV) IN VENIPUNCTURE WHOLE BLOOD SPECIMENS (EDTA, SODIUM HEPARIN, LITHIUM HEPARIN, AND SODIUM CITRATE) FROM INDIVIDUALS 15 YEARS OR OLDER. THE ORAQUICK HCV RAPID ANTIBODY TEST RESULTS, IN CONJUNCTION WITH OTHER LABORATORY RESULTS AND CLINICAL INFORMATION, MAY BE USED TO PROVIDE PRESUMPTIVE EVIDENCE OF INFECTION WITH HCV (STATE OF INFECTION OR ASSOCIATE

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
OraQuick Ebola Rapid Antigen Test (DEN190025)OraSure Technologies, Inc.2019-10-10
COMPOUND W FREEZE OFF WART REMOVAL SYSTEM (K060859)OraSure Technologies, Inc.2006-07-18
HISTOFREEZER WART REMOVAL SYSTEM OR OTHER PROPRIETARY NAME (K023487)OraSure Technologies, Inc.2003-03-20
OTI BENZODIAZEPINES INTERCEPT MICRO-PLATE EIA MODEL #1110I (K013882)OraSure Technologies, Inc.2002-04-17
UPLINK TEST SYSTEM (K020371)OraSure Technologies, Inc.2002-04-03
INTERCEPT ORAL FLUID DRUG TEST ORAL SPECIMEN COLLECTION DEVICE, MODEL 503-XXXX (K011057)OraSure Technologies, Inc.2001-06-06
STC CANNABINOIDS INTERCEPT MICRO-PLATE EIA, MODEL 1118I (K002375)OraSure Technologies, Inc.2001-01-26
STC BARBITURATES INTERCEPT MICRO-PLATE EIA, MODEL 1108I (K001976)OraSure Technologies, Inc.2000-12-06